Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$332K Buy
2,584
+619
+32% +$72.5K 0.06% 104
2026
Q1
$236K Buy
1,965
+7
+0.4% +$808 0.05% 115
2025
Q4
$206K Buy
+1,958
New +$184K 0.05% 123
2024
Q4
Sell
-1,923
Closed -$218K 94
2024
Q3
$218K Buy
1,923
+5
+0.3% +$594 0.06% 82
2024
Q2
$237K Sell
1,918
-595
-24% -$76.6K 0.07% 73
2024
Q1
$331K Buy
2,513
+623
+33% +$76.8K 0.11% 51
2023
Q4
$206K Sell
1,890
-595
-24% -$61.8K 0.08% 76
2023
Q3
$256K Buy
2,485
+172
+7% +$18.5K 0.11% 58
2023
Q2
$266K Buy
+2,313
New +$263K 0.12% 53
2018
Q3
Sell
-2,595
Closed -$150K 221
2018
Q2
$150K Buy
+2,595
New +$146K 0.12% 72
2018
Q1
Sell
-3,179
Closed -$171K 216
2017
Q4
$171K Buy
3,179
+709
+29% +$39.3K 0.15% 57
2017
Q3
$151K Buy
+2,470
New +$150K 0.13% 69

Other funds holding MRK

Landaas & Company's MRK Position: Q2 2026 in Review

Landaas & Company increased its Merck (MRK) stake by 32% in Q2 2026, buying an estimated $72.5K and bringing the position to 2,584 shares worth $332K. The position accounts for 0.06% of the portfolio, ranked #104.

Landaas & Company first reported a position in MRK in Q3 2017 and has held it in 12 quarters since. 1,570 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Landaas & Company held 2,584 shares of Merck worth $332K as of Q2 2026.
  • Landaas & Company bought 619 Merck shares in Q2 2026, an estimated $72.5K.
  • Merck made up 0.06% of Landaas & Company's portfolio in Q2 2026, its #104 holding.
  • Landaas & Company first reported a position in Merck in Q3 2017 and has held it in 12 quarters since.
  • 1,570 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Landaas & Company's 13F filing for Q2 2026, filed 21 Jul 2026.